

Tretten Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Physician's Name:	's Date of Birth:		
Physician's Name: NPI#: _ NPI#: _			
Specialty: NPI#: _			
Physician Office Telephone: Physici			
• • • • •	Physician Office Fax:		
Referring Provider Info: 🛛 Same as Requesting Provider			
Name: NPI#:			
Fax: Phone:			
Rendering Provider Info:	as Requesting Provider		
Name: NPI#:			
Fax: Phone:			

Req	uired	Demos	gra	phic	Information:
	-				

Patient Weight:	kg	
Patient Height:	cm	
Please indicate the place of service for the	requested drug:	
Ambulatory Surgical	🗖 Home	$\square Off$ Campus Outpatient Hospital
On Campus Outpatient Hospital	Office	
Drug Information:		
Strength/Measure		$Units \square ml \square Gm \square mg \square ea \square Un$
Directions(sig)		Route of administration
Dosing frequency		

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tretten SGM 2985-A – 04/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com

Clinical Criteria Questions:

What is the ICD-10 code?

1. What is the diagnosis?

Congenital factor XIII A-subunit deficiency, Continue to 2

Congenital factor XIII B-subunit deficiency, *Continue to 2*

□ Other, please specify. _____, Continue to 2

2. Is the request for continuation of therapy?

□ Yes, Continue to 4

 \square No, *Continue to 3*

3. Is Tretten being requested for the prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency?

□ Yes, No Further Questions

□ No, No Further Questions

4. Is the patient experiencing benefit from therapy (e.g., reduced frequency or severity of bleeds)?

□ Yes, No Further Questions

□ No, No Further Questions

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Tretten SGM 2985-A – 04/2023.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com